COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies

Mol Biol Rep. 2021 Mar;48(3):2917-2928. doi: 10.1007/s11033-021-06333-w. Epub 2021 Apr 10.

Abstract

The renin-angiotensin-aldosterone system and its metabolites play an important role in homeostasis of body, especially the cardiovascular system. In this study, we discuss the imbalance of multiple systems during the infection and the importance of therapeutic choice, dosing, and laboratory monitoring of cardiac and anti-coagulant therapies in COVID-19 patients. The crosstalk between angiotensin, kinin-kallikrein system, as well as inflammatory and coagulation systems plays an essential role in COVID-19. Cardiac complications and coagulopathies imply the crosstalks between the mentioned systems. We believe that the blockage of bradykinin can be a good option in the management of COVID-19 and CVD in patients and that supportive treatment of respiratory and cardiologic complications is needed in COVID-19 patients. Ninety-one percent of COVID-19 patients who were admitted to hospital with a prolonged aPTT were positive for lupus anticoagulant, which increases the risk of thrombosis and prolonged aPTT. Therefore, the question that is posed at this juncture is whether it is safe to use the prophylactic dose of heparin particularly in those with elevated D-dimer levels. It should be noted that timing is of high importance in anti-coagulant therapy; therefore, we should consider the level of D-dimer, fibrinogen, drug-drug interactions, and risk factors during thromboprophylaxis administration. Fibrinogen is an independent predictor of resistance to heparin and should be considered before thromboprophylaxis. Alteplase and Futhan might be a good choice to assess the condition of heparin resistance. Finally, the treatment option, dosing, and laboratory monitoring of anticoagulant therapy are critical decisions in COVID-19 patients.

Keywords: Bradykinin; Cardiac complications; Coagulation; Cytokine storm; SARS-CoV-2.

Publication types

  • Review

MeSH terms

  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use
  • Bradykinin / blood
  • COVID-19* / complications
  • COVID-19* / immunology
  • COVID-19* / physiopathology
  • COVID-19* / therapy
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / virology
  • Fibrin Fibrinogen Degradation Products / analysis
  • Humans
  • Inflammation / immunology
  • Inflammation / virology
  • Kallikreins / blood
  • Renin-Angiotensin System / immunology
  • Renin-Angiotensin System / physiology
  • SARS-CoV-2*
  • Thrombosis* / drug therapy
  • Thrombosis* / prevention & control
  • Thrombosis* / virology

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • Kallikreins
  • Bradykinin